Literature DB >> 21524189

Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases.

Petra Jančová1, Michal Siller, Eva Anzenbacherová, Vladimír Křen, Pavel Anzenbacher, Vilím Simánek.   

Abstract

The flavonolignan silybin, the main component of silymarin, extract from the seeds of Silybum marianum, is used mostly as a hepatoprotectant. Silybin is almost 1:1 mixture of two diastereomers A and B. The individual UDP-glucuronosyltransferases (UGTs) contributing to the metabolism of silybin diastereomers have not been identified yet. In this study, the contribution of UGTs to silybin metabolism was examined. The potential silybin metabolites were formed in vitro by incubating silybin (i) with the human liver microsomal fraction, (ii) with human hepatocytes and finally (iii) with 12 recombinant UGTs (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15 and 2B17). High-performance liquid chromatographic (HPLC) techniques with UV detection and additionally MS detection were used for metabolite identification. Hepatocytes and microsomes formed silybin A-7-O-β-D-glucuronides, B-7-O-β-D-glucuronides, A-20-O-β-D-glucuronides and B-20-O-β-D-glucuronides. With recombinant UGTs, the major role of the UGT1A1, 1A3, 1A8 and 1A10 enzymes but also of the UGT1A6, 1A7, 1A9, 2B7 and 2B15 in the stereoselective reactions leading to the respective silybin glucuronides was confirmed. UGT1A4, UGT2B4 and UGT2B17 did not participate in silybin glucuronidation. The predominant formation of 7-O-β-D-glucuronides and the preferential glucuronidation of silybin B diastereomer in vitro by human UGTs were confirmed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21524189     DOI: 10.3109/00498254.2011.573017

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  13 in total

1.  Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides.

Authors:  Brandon T Gufford; Tyler N Graf; Noemi D Paguigan; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2015-08-27       Impact factor: 3.922

2.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

3.  Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study.

Authors:  Wen-Yi Li; Guo Yu; Renee M Hogan; Rajesh Mohandas; Reginald F Frye; Eric Gumpricht; John S Markowitz
Journal:  Clin Ther       Date:  2017-12-19       Impact factor: 3.393

4.  An ex vivo approach to botanical-drug interactions: a proof of concept study.

Authors:  Xinwen Wang; Hao-Jie Zhu; Juliana Munoz; Bill J Gurley; John S Markowitz
Journal:  J Ethnopharmacol       Date:  2015-01-24       Impact factor: 4.360

5.  Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Authors:  Sarah J Schrieber; Roy L Hawke; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Catherine M Meyers; Edward Doo; Michael W Fried
Journal:  Drug Metab Dispos       Date:  2011-08-24       Impact factor: 3.922

6.  Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction.

Authors:  Brandon T Gufford; Gang Chen; Ana G Vergara; Philip Lazarus; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2015-06-12       Impact factor: 3.922

7.  Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation.

Authors:  Brandon T Gufford; Gang Chen; Philip Lazarus; Tyler N Graf; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2014-07-09       Impact factor: 3.922

8.  An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.

Authors:  Hao-Jie Zhu; Bryan J Brinda; Kenneth D Chavin; Hilary J Bernstein; Kennerly S Patrick; John S Markowitz
Journal:  Drug Metab Dispos       Date:  2013-07-08       Impact factor: 3.579

9.  Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.

Authors:  Ying Xie; Sonia R Miranda; Janelle M Hoskins; Roy L Hawke
Journal:  Molecules       Date:  2017-01-15       Impact factor: 4.411

10.  The Effect of Silymarin Flavonolignans and Their Sulfated Conjugates on Platelet Aggregation and Blood Vessels Ex Vivo.

Authors:  Jana Pourová; Lenka Applová; Kateřina Macáková; Marie Vopršalová; Thomas Migkos; Roger Bentanachs; David Biedermann; Lucie Petrásková; Václav Tvrdý; Marcel Hrubša; Jana Karlíčková; Vladimír Křen; Kateřina Valentová; Přemysl Mladěnka
Journal:  Nutrients       Date:  2019-09-24       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.